mRNA-based therapies: Preclinical and clinical applications.

Qureischi, Musga; Mohr, Julia; Arellano-Viera, Estibaliz; Knudsen, Sarah Elspeth; Vohidov, Farrukh; Garitano-Trojaola, Andoni

Qureischi, Musga; Mohr, Julia; Arellano-Viera, Estibaliz; Knudsen, Sarah Elspeth; Vohidov, Farrukh; Garitano-Trojaola, Andoni.

Afiliação

Qureischi M; BioNTech SE, Mainz, Germany.
Mohr J; BioNTech SE, Mainz, Germany.
Arellano-Viera E; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Knudsen SE; Independent Scholar, Watertown, MA, United States.
Vohidov F; BioNTech US, Cambridge, MA, United States.
Garitano-Trojaola A; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany. Electronic address: garitano_a@ukw.de.

Int Rev Cell Mol Biol ; 372: 1-54, 2022.

Article em En | MEDLINE | ID: mdl-36064262

Assuntos

COVID-19; Neoplasias; COVID-19/terapia; Humanos; Imunoterapia; Pandemias; Proteínas; RNA Mensageiro/genética; RNA Mensageiro/metabolismo

Palavras-chave

Autoimmunity; Cancer immunotherapy; Cell reprogramming; Chemical modifications; Gene editing; In vitro-transcribed mRNA; Infectious disease; mRNA delivery

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google